BioArctic Partner Eisai Report the US FDA Acceptance of BLA for Lecanemab to Treat Alzheimer's Disease
- The US FDA has accepted the BLA under the accelerated approval for lecanemab to treat MCI due to AD & mild AD with confirmed presence of amyloid pathology in the brain. The PDUFA action date for Eisai's application which was finished in early May 2022 is Jan 6, 2023
- The P-III (Clarity AD) trial for lecanemab in early AD is ongoing in 1795 patients with expected results in 2022. The company plans to file for manufacturing & marketing approval of lecanemab in the US, Japan & EU at an end of Q1’23, based on the (Clarity AD) trial results
- Lecanemab has received BTD & FTD from the FDA & is being evaluated in the P-III study for symptomatic early AD. Upon an acceptance of BLA by the US FDA, BioArctic receive a $15.83M milestone
Ref: PRNewswire | Image: BioArctic
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at [email protected].